Skip to main content

Table 1 Clinical and pathological features of the study population

From: The role of opioids in cancer response to immunotherapy

 

Total

OPIODS

NO OPIODS

p

N. (%)

N. (%)

N. (%)

193 (100)

42 (100)

151 (100)

Sex

 

 Male

120 (62)

25 (60)

95(63)

0.689

 Female

73 (38)

17 (40)

56 (37)

 

Age (years)

 

Median

    

 < 65

61 (32)

14 (33)

47 (31)

 

 65–75

78 (40)

21 (50)

57 (38)

57 (38)

 

 > 75

53 (53)

7 (17)

46 (31)

0.171

Missed

1 (1)

   

Diagnosis

    

 NSCLC

59 (30)

21(62)

33 (22)

 < 0.0001

 Melanoma

99 (51)

7 (17)

92 (61)

 

 Renal Cancer

28 (14)

5 (12)

23 (15)

 

 Urothelial Cancer

5 (3)

3 (7)

2 (1)

 

 Merkel Tumor

1 (0.5)

1 (2)

0

 

 Colon Cancer

1 (0.5)

0

1 (1)

 

ECOG PS

 0

94 (49)

9 (21)

85 (56)

 

 ≥1

99 (51)

33 (79)

66 (44)

 < 0.0001

Comorbidity

 0–1

122 (63)

29 (69)

93 (62)

0.375

 ≥2

71 (37)

13 (31)

58 (38)

 

Immunotherapy, drug name

 Nivolumab

121 (63)

26 (62)

95 (63)

0.145

 Pembrolizumab

60 (31)

11 (26)

49 (32)

 

 Atezolizumab

11 (6)

4 (10)

7 (5)

 

 Avelumab

1 (0.5)

1 (2)

0

 

Immunotherapy setting

 First line

91 (47)

11 (26)

80 (53)

 

 Second line

69 (36)

21 (50)

48 (32)

0.009

 Beyond II-line

33 (17)

10 (24)

23 (15)

 

Antibiotics/Antifungals

 Yes

21 (11)

8 (19)

13 (9)

0.055

 Not

172 (89)

34 (81)

138 (91)

 

Corticosteroids

 Yes

44 (23)

20 (48)

24 (16)

 < 0.0001

 Not

148 (77)

22 (52)

126 (84)

 

Opiods

Yes

42 (22)

-

-

 

Not

151 (78)

-

-

 

Tumor burden

 Low

91 (47)

12 (29)

79 (52)

 

 High

102 (53)

30 (71)

72 (48)

0.006

  1. PS ECOG performance status, NSCLC non-small cell lung cancer, RCC renal cell carcinoma